Literature DB >> 11526524

Patch testing with serial dilutions of budesonide, its R and S diastereomers, and potentially cross-reacting substances.

M Isaksson1, M Bruze, J P Lepoittevin, A Goossens.   

Abstract

BACKGROUND: Budesonide, a marker for corticosteroid allergy, is a 1:1 mixture of 2 diastereomers, the R and S, present in all commercial formulations. Budesonide is said to cross-react with group B substances through the R and S diastereomer and some group D substances only through the S diastereomer.
OBJECTIVE: To investigate the cross-reactivity pattern between the R and S diastereomers and 4 potentially cross-reacting substances, 2 from group B and 2 from group D.
METHODS: By patch testing 10 patients hypersensitive to budesonide with a serial dilution of budesonide, the R and S diastereomer, triamcinolone acetonide, amcinonide, prednicarbate, and hydrocortisone-17-butyrate.
RESULTS: Nine of 10 patients reacted to budesonide and the S diastereomer. Seven of 9 to the R diastereomer. Each of the 9 patients with S diastereomer allergy reacted to the group B and/or group D substances. Five patients reacted to triamcinolone acetonide, not to 1.0% but only to 0.0010% and 0.00010%.
CONCLUSION: The R and S diastereomers can induce positive patch test reactions in budesonide-hypersensitive individuals. The potential of budesonide to cross-react with substances from group B and D might be explained by the presence of the 2 diastereomers. When patch testing with triamcinolone acetonide, much lower concentrations than recommended should be used. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526524

Source DB:  PubMed          Journal:  Am J Contact Dermat        ISSN: 1046-199X


  1 in total

1.  Anaphylaxis following intralesional triamcinolone acetonide (Kenacort) injection.

Authors:  Wannada Laisuan; Chamard Wongsa; Nizchapha Dchapaphapeaktak; Malinee Tongdee; Jidapa Chatmapanrangsee; Ticha Rerkpattanapipat
Journal:  Asia Pac Allergy       Date:  2017-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.